Höffken K
Klinik für Innere Medizin II, Friedrich-Schiller-Universität Jena, Germany.
Cancer Treat Rev. 1993 Apr;19 Suppl B:37-44. doi: 10.1016/0305-7372(93)90006-d.
Inhibition of the aromatase enzyme system has become an established means of hormonal treatment for hormone-responsive advanced breast cancer. The widest clinical experience is with aminoglutethimide, which achieves around 30% objective remissions of metastatic disease for up to 1 year. Due to the sometimes serious side-effects of this drug, preclinical and clinical investigations have been undertaken and have yielded a number of steroidal and non-steroidal aromatase inhibitors that have been shown in early or mature clinical trials to give objective disease remissions similar to those with aminoglutethimide but with less toxicity. There is thus good reason to believe that newer aromatase inhibiting drugs will soon be available for routine use in patients with breast cancer. This paper summarizes our experience and reviews data from other groups.
抑制芳香化酶系统已成为激素反应性晚期乳腺癌激素治疗的既定方法。临床经验最丰富的是氨鲁米特，它能使转移性疾病的客观缓解率达到约30%，持续长达1年。由于该药物有时会产生严重的副作用，因此已经开展了临床前和临床研究，并产生了一些甾体和非甾体芳香化酶抑制剂，这些抑制剂在早期或成熟的临床试验中已显示出能产生与氨鲁米特相似的客观疾病缓解，但毒性较小。因此，有充分的理由相信，新型芳香化酶抑制药物很快将可用于乳腺癌患者的常规治疗。本文总结了我们的经验并回顾了其他研究组的数据。
